Literature DB >> 17613015

Degradable cisplatin-releasing core-shell nanogels from zwitterionic poly(beta -aminoester)-graft-PEG for cancer chemotherapy.

Wei Jin1, Peisheng Xu, Yihong Zhan, Youqing Shen, Edward A Van Kirk, Brenda Alexander, William J Murdoch, Lijian Liu, Dale D Isaak.   

Abstract

Cisplatin conjugated onto macromolecules or loaded in micelles can be preferentially delivered to tumors to minimize its toxicity to healthy tissues and increase its drug efficacy. Herein, we report cisplatin-containing nanogels possibly useful for targeted delivery of cisplatin. Carboxylic acid-functionalized poly(beta -aminoester)graft-poly(ethylene glycol) copolymers were synthesized by cocondensation polymerization of piperazine with 2,2-bis(acryloxymethyl)propionic acid, PEG 2,2-bis(acryloxymethyl)propionate macromonomer (mPEG). The graft copolymers formed 100-200 nm nanogels with low size-distribution by the complexation of their carboxylic groups with cisplatin. The nanogels were negatively charged and had a PEG outer layer. Thus, they had "stealth properties" suitable for in vivo applications. The nanogels had significantly lower in vitro cytotoxicity to SKOV-3 ovarian cancer cells than free cisplatin, but similar anticancer activity toward SKOV-3 tumors xenografted to immunocompromised mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613015     DOI: 10.1080/10717540601036856

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  4 in total

Review 1.  Nanogels as pharmaceutical carriers: finite networks of infinite capabilities.

Authors:  Alexander V Kabanov; Serguei V Vinogradov
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 2.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

3.  F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo.

Authors:  Ira Winer; Shouyan Wang; Yong-Eun Koo Lee; Youg-Eun Koo Lee; Wenzhe Fan; Yusong Gong; Daniela Burgos-Ojeda; Greg Spahlinger; R Kopelman; Ronald J Buckanovich
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

4.  Targeted delivery of platinum-taxane combination therapy in ovarian cancer.

Authors:  Swapnil S Desale; Kruti S Soni; Svetlana Romanova; Samuel M Cohen; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-09-14       Impact factor: 9.776

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.